Boehringer Ingelheim announces interim results from a Phase III trial in HIV patients co-infected with chronic hepatitis C
4 March 2013 | By Boehringer Ingelheim
Interim study results from STARTversoTM 4...
List view / Grid view
News
FDA accepts Biogen Idec’s Biologics License Application for first long-lasting factor IX therapy for hemophilia B
4 March 2013 | By Biogen Idec
“We are encouraged by the FDA’s acceptance of our application..."
Daiichi Sankyo announces organizational restructuring as of April 1, 2013
4 March 2013 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced the following organizational changes taking place from April 1, 2013...
Baby born with AIDS virus appears to have been cured
3 March 2013 | By University of Mississippi
A baby born with the virus that causes AIDS appears to have been cured, scientists announced Sunday...
Sanofi and Regeneron report positive proof-of-concept data for Dupilumab
2 March 2013 | By Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting…
Novartis receives EU approval for Ilaris®
1 March 2013 | By Novartis
Novartis announced that the European Commission has approved llaris (canakinumab, ACZ885)...
PerkinElmer hosts Revolutionaries for Global Health Summit in Brussels
1 March 2013 | By Edelman (On behalf of PerkinElmer)
Revolutionaries for Global Health Summit, 5 -6 March 2013, Brussels...
Bruce Kuhlik and Merck Honored by PBI for commitment to pro bono
28 February 2013 | By Merck
Merck announces that the Pro Bono Institute (PBI) has selected Executive Vice President Bruce Kuhlik as the winner...
ViiV Healthcare announces a voluntary licence agreement with the Medicines Patent Pool to increase access to HIV medicines for children
28 February 2013 | By
Agreement brings the number of voluntary...
Boehringer Ingelheim announces initiation of pivotal trial investigating volasertib* in patients with acute myeloid leukaemia
28 February 2013 | By Boehringer Ingelheim
Boehringer Ingelheim invests in rare diseases...
Novartis collaboration aims to eliminate rheumatic heart disease (RHD) in Zambia
28 February 2013 | By Novartis
Novartis today announced that it has launched an effort to eliminate rheumatic heart disease in Zambia in collaboration with the Lusaka...
EURORDIS awards Celgene Corporation for excellence in medical innovation in rare diseases
27 February 2013 | By Weber Shandwick
EURORDIS announced that Celgene Corporation has been awarded the prestigious EURORDIS Company Award for excellence in the field of rare diseases...
Genzyme receives company award from European Organisation for Rare Diseases
27 February 2013 | By Genzyme
Sanofi and its subsidiary Genzyme announced today that Genzyme has received a Company Award from EURORDIS...
Join Lonza’s March webinar on endotoxin detection methods
There are many Limulus Amebocyte Lysate (LAL) methods commercially available today. Hence, Lonza is hosting a free, 60-minute webinar entitled "Endotoxin Detection – Which Method Is Best for Me" at two different dates and times.
Academy and Alzheimer’s Drug Discovery Foundation award challenge grant for research of biomarkers in Alzheimer’s disease
26 February 2013 | By The New York Academy of Sciences
The Academy awarded a challenge grant...
